Thermo Fisher Scientific has announced a strategic collaboration with SHL Medical, a provider of advanced drug delivery systems, alongside an expansion of sterile fill-finish and autoinjector final assembly capacity at its Ridgefield, NJ site.
Shutterstock - PeopleImages
Collaboration concept.
Together, these investments establish a fully integrated U.S.-based offering spanning sterile manufacturing, device assembly and commercial packaging for drug-device combination products.
Demand for patient-centric, self-administered injectable therapies continues to grow across multiple therapeutic areas including autoimmune diseases, inflammatory conditions, and other chronic diseases. To meet this need, Thermo Fisher is expanding pre-filled syringe (PFS) fill-finish and device assembly in Ridgefield. In parallel, its strategic collaboration with SHL Medical enables integration of SHL Medical’s Molly autoinjector platform with Thermo Fisher’s sterile manufacturing network, creating a seamless, end-to-end solution from drug product to finished device.
Thermo Fisher acquired the Ridgefield facility from Sanofi in September 2025 as part of its strategy to strengthen its U.S. manufacturing footprint. The site is being developed as a premier North American hub for integrated sterile fill-finish, autoinjector final assembly and packaging, increasing domestic capacity to support customer supply chains.
“The collaboration with SHL Medical, a global leader in autoinjectors, and our expansion in Ridgefield are important steps in helping our customers meet growing demand,” said Michelle Logan, vice president, Drug Product – Steriles, North America, Thermo Fisher. “By fully integrating fill-finish with device assembly, we can simplify supply chains, accelerate timelines and ultimately support our customers in delivering critical therapies to patients more efficiently.”
Under the strategic, non-exclusive collaboration, Thermo Fisher and SHL Medical will provide integrated support for SHL Medical’s Molly autoinjector platform at the Ridgefield site, including device final assembly, packaging and distribution. The collaboration is designed to simplify development and manufacturing for pharmaceutical and biotechnology customers, supporting a streamlined path from drug product manufacturing through commercialization.
“This collaboration with Thermo Fisher represents a significant milestone for SHL Medical and for the customers we jointly serve,” said Markus Puusepp, chief Ggowth officer, SHL Medical. “By combining SHL Medical’s proven Molly® autoinjector platform and global device expertise with Thermo Fisher’s leading sterile fill-finish and commercial manufacturing capabilities, we are creating a powerful, integrated solution. This installation in Ridgefield underscores our shared commitment to supporting the growing demand for high-quality, patient-centric combination products and accelerating time to market for innovative therapies worldwide.”
The addition of autoinjector capabilities in Ridgefield complements Thermo Fisher’s global network, including sites in Allentown, Pa., Horsham, UK, and planned capacity in Greenville, N.C., creating a scalable platform across development and commercial stages. Continued investments across its steriles network, including Greenville, N.C., Ferentino, Italy and expansion in APAC, further strengthen the company’s ability to support customers with integrated, global manufacturing solutions.